TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30130346

Group type: EXPERIMENTAL
Intervention: Contraction-associated heart rate deceleration pattern in hypovolemic women (defined by admission pulse pressure <45 mm Hg)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Contraction-associated heart rate deceleration pattern in euvolemic women (defined by admission pulse pressure ≥50 mm Hg)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Postepidural FHR abnormalities
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Diastolic hypotension
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Need for resuscitative interventions
Number of subjects: 388
Study: 26620496

Group type: EXPERIMENTAL
Intervention: MK-5108 monotherapy (Panel1) at doses ranging from 200 to 1800 mg, administered p.o. BID Q12h on days 1-2 in 14-21 day cycles.
Number of subjects: 35

Group type: COMPARATOR
Intervention: MK-5108 in combination with docetaxel (Panel2) at 450 mg/day, administered IV docetaxel 60 mg/m2.
Number of subjects: 35
Study: 25416527

Group type: EXPERIMENTAL
Intervention: TRIGGER trial - open-label cluster randomised trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAPPS trial - open-label trial
Number of subjects: 0
Study: 22122738

Group type: EXPERIMENTAL
Intervention: Ablative fractional laser therapy (10,600-nm FLT, 10 mJ/microbeam, 35-45% coverage) for three to five sessions
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser therapy (1,550-nm FLT, 15 mJ/microbeam, 14-20% coverage) for three to five sessions
Number of subjects: 18

Group type: COMPARATOR
Intervention: Topical bleaching
Number of subjects: 18
Study: 19853332

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of glutamate
Number of subjects: 69

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both groups (glutamate and saline)
Number of subjects: 69
Study: 17653058

Group type: EXPERIMENTAL
Intervention: General anesthesia with ketamine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: General anesthesia without ketamine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Local (peribulbar) anesthesia
Number of subjects: 37
Study: 14990914

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 11075876

Group type: EXPERIMENTAL
Intervention: Lower calcium intake and higher phosphorus intake
Number of subjects: 27062

Group type: COMPARATOR
Intervention: Calcium and phosphorus intake
Number of subjects: 27062
Study: 9353602

Group type: EXPERIMENTAL
Intervention: Three meals per day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Nine meals per day
Number of subjects: 13
Study: 8222514

Group type: EXPERIMENTAL
Intervention: Head-out water immersion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 8
Study: 3898832

Group type: EXPERIMENTAL
Intervention: Sucralfate (900 mg before meals and at bedtime)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 138
Study: 31574879

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) applied for the treatment of infected dentin, followed by restoration with high viscosity glass ionomer cement.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving removal of softened dentin with sharp dentine curettes and restoration with high viscosity glass ionomer cement.
Number of subjects: 0
Study: 28005265

Group type: EXPERIMENTAL
Intervention: tabalumab 100 mg
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: tabalumab 300 mg
Number of subjects: 220

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: low baseline BAFF expression
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: high baseline BAFF expression
Number of subjects: 220
Study: 25951308

Group type: EXPERIMENTAL
Intervention: Amorphous calcium phosphate (ACP) containing resin-based sealant (Aegis)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Fluoride-containing resin-based sealant (Helioseal F)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Non-fluoride resin-based sealant (Helioseal)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Helioseal FS
Number of subjects: 75

Group type: COMPARATOR
Intervention: Aegis FS
Number of subjects: 75
Study: 24814500

Group type: EXPERIMENTAL
Intervention: Moderate dose of LPS (0.8 ng/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose LPS (0.4 ng/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo control group)
Number of subjects: 0
Study: 21080416

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19378700

Group type: EXPERIMENTAL
Intervention: Crisis Resolution Team (CRT) care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard services
Number of subjects: 0
Study: 17582069

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (0.625 mg per day)
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (with at least 80% adherence)
Number of subjects: 1064
Study: 15105237

Group type: EXPERIMENTAL
Intervention: PEEP (10 cm H(2)O) during induction with 100% oxygen for 5 min and mechanical ventilation via face mask
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no PEEP or continuous positive airway pressure)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PEEP group
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 10735926

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg b.d.) with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Omeprazole (20 mg b.d.) with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Number of subjects: 192
Study: 9177359

Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg testosterone cypionate biweekly for 12 months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1539524

Group type: EXPERIMENTAL
Intervention: Early initiation of warfarin (within 48 hours of heparin)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Late initiation of warfarin (96 hours or later after heparin)
Number of subjects: 119
Study: 3873713

Group type: EXPERIMENTAL
Intervention: Esophageal transection
Number of subjects: 76

Group type: COMPARATOR
Intervention: Injection sclerotherapy
Number of subjects: 76
Study: 30952558

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 28795584

Group type: EXPERIMENTAL
Intervention: SMSMessenger application for sending automated text message reminders
Number of subjects: 0
Study: 27539884

Group type: EXPERIMENTAL
Intervention: Haptoglobin 2-2 genotype
Number of subjects: 1303

Group type: COMPARATOR
Intervention: Intensive therapy
Number of subjects: 1303

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1303
Study: 24326799

Group type: EXPERIMENTAL
Intervention: Oral Misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous Ergometrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous Oxytocin
Number of subjects: 0
Study: 23584366

Group type: EXPERIMENTAL
Intervention: Modified-release prednisone (MR-pred) 5 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20527506

Group type: EXPERIMENTAL
Intervention: CrossAction Pro‐Health (CAPH)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CrossAction (CA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exceed (EX)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Advantage 123 (ADV 123)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Indicator (IND)
Number of subjects: 10
Study: 18833969

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study: 16620136

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg/kg
Number of subjects: 50
Study: 14669764

Group type: EXPERIMENTAL
Intervention: Noninvasive continuous positive airway pressure ventilation (CPAP) using a new helmet interface
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard facial mask for CPAP
Number of subjects: 22
Study: 10979160

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment tailored to individual symptoms and standardized component for health and immune function
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control-needling group with clinically irrelevant acupuncture points
Number of subjects: 11
Study: 8971289

Group type: EXPERIMENTAL
Intervention: fedotozine (30 mg t.d.s.)
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 1593505

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural problem solving treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 30426300

Group type: EXPERIMENTAL
Intervention: ATP (160 mcg/kg/min)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Adenosine (140 mcg/kg/min)
Number of subjects: 33
Study: 28695632

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 31
Study: 26381535

Group type: EXPERIMENTAL
Intervention: Composite index of exercise capacity (EC) and exercise heart rate responses
Number of subjects: 1531

Group type: EXPERIMENTAL
Intervention: Exercise test risk score (calculated as the sum of hazard ratios related to abnormal EC, CRI, and HRR)
Number of subjects: 1531

Group type: EXPERIMENTAL
Intervention: Addition of exercise test risk score to established risk model
Number of subjects: 1531
Study: 23922063

Group type: EXPERIMENTAL
Intervention: Care guide intervention
Number of subjects: 2135

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2135
Study: 21071171

Group type: EXPERIMENTAL
Intervention: Virtual reality using Wii gaming technology (VRWii)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Standard occupational therapy (SOT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 19898595

Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg VO e/12h) with Amoxicillin (1g VO e/12h) and Clarithromycin (500 mg VO e/12h)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Omeprazole (20 mg VO e/12h) with Amoxicillin (1g VO e/12h) and Clarithromycin (500 mg VO e/12h)
Number of subjects: 83
Study: 17767050

Group type: EXPERIMENTAL
Intervention: Lymphoplasmapheresis (LPE) in addition to medical treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Medical treatment only (Control)
Number of subjects: 66
Study: 15557008

Group type: EXPERIMENTAL
Intervention: Hyperoxic gas mixture
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixture
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hyperoxic CO(2) rebreathing
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hypoxic CO(2) rebreathing
Number of subjects: 28

Group type: COMPARATOR
Intervention: CO(2) rebreathing
Number of subjects: 28
Study: 12101789

Group type: EXPERIMENTAL
Intervention: Metoprolol (initial dose of 15 mg intravenously, followed by 100 mg/d orally)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no metoprolol administered)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 35
Study: 11225795

Group type: EXPERIMENTAL
Intervention: cHUT (conventional nitroglycerin test)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: aHUT (accelerated nitroglycerin test)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: cHUT drug-free phase
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: cHUT NTG phase
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: aHUT
Number of subjects: 84
Study: 7484845

Group type: EXPERIMENTAL
Intervention: Dietary fish oil
Number of subjects: 0
Study: 2080948

Group type: EXPERIMENTAL
Intervention: Combination of co-dergocrine mesilate and nifedipine (Pontuc)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 22
Study: 469515

Group type: EXPERIMENTAL
Intervention: 1 g of L‐tryptophan
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1/4 g of L‐tryptophan
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1/2 g of L‐tryptophan
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30791804

Group type: EXPERIMENTAL
Intervention: sifalimumab (IV 1.0, 3.0, and 10.0 mg/kg or subcutaneous 100 mg every 2 weeks; IV 600 and 1200 mg every 6 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: sifalimumab (same doses as Stage I or 600 mg IV every 4 weeks if enrolled later)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: sifalimumab
Number of subjects: 51
Study: 30248039

Group type: EXPERIMENTAL
Intervention: Mulligan mobilization with conventional physiotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physiotherapy (Control)
Number of subjects: 30
Study: 28137336

Group type: EXPERIMENTAL
Intervention: 8-week group Cognitive Behavioural Therapy for perfectionism (CBT-P)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 8-week waitlist followed by CBT-P
Number of subjects: 11
Study: 23828493

Group type: EXPERIMENTAL
Intervention: SRP + aPDT
Number of subjects: 20

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 20
Study: 23275597

Group type: EXPERIMENTAL
Intervention: Pipeline embolization device
Number of subjects: 96
Study: 21905402

Group type: EXPERIMENTAL
Intervention: 5% NovaMin toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8% arginine toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 0
Study: 19395071

Group type: EXPERIMENTAL
Intervention: Postoperative morphine-bupivacaine PCEA
Number of subjects: 135

Group type: COMPARATOR
Intervention: Postoperative intravenous morphine PCA
Number of subjects: 135
Study: 16882803

Group type: EXPERIMENTAL
Intervention: Car bed
Number of subjects: 67

Group type: COMPARATOR
Intervention: Car safety seat
Number of subjects: 67
Study: 11425054

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 9284850

Group type: EXPERIMENTAL
Intervention: 150 mg single dose of sertraline (after a single dose of desipramine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 mg single dose of sertraline (after multiple doses of desipramine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 mg single dose of sertraline (after a single dose of imipramine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 mg single dose of sertraline (after multiple doses of imipramine)
Number of subjects: 12
Study: 8511496

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine twice daily (group 1)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine twice daily (group 2)
Number of subjects: 440

Group type: COMPARATOR
Intervention: 150 mg ranitidine twice daily (group 3)
Number of subjects: 440
Study: 3630806

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 40

Group type: COMPARATOR
Intervention: Smoking Deprivation
Number of subjects: 40
Study: 29113986

Group type: EXPERIMENTAL
Intervention: 500 mg MPX (low dose)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 4,000 mg MPX (high dose)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: MPX (pooled treatment arms) in SOD2 Alanine/Alanine genotype patients
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (SOD2 Alanine/Alanine genotype patients)
Number of subjects: 125
Study: 27827328

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Dichotomized CBS (at CBS of 6)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Intra-arterial treatment in high CBS group
Number of subjects: 499
Study: 24726142

Group type: EXPERIMENTAL
Intervention: Neoadjuvant sorafenib treatment for 4 weeks before tumor nephrectomy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (matched with regard to prognostic parameters)
Number of subjects: 10
Study: 23746263

Group type: EXPERIMENTAL
Intervention: Nutritional intake assessment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Energy and protein intake
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: In-patient malnutrition incidence
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Barriers to intake
Number of subjects: 44
Study: 20614124

Group type: EXPERIMENTAL
Intervention: Telmisartan 40/80 mg once daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18413151

Group type: EXPERIMENTAL
Intervention: Late luteal phase in women with PMDD
Number of subjects: 29

Group type: COMPARATOR
Intervention: Follicular phase in women with PMDD
Number of subjects: 29

Group type: COMPARATOR
Intervention: Late luteal phase in Control women
Number of subjects: 29
Study: 15882229

Group type: EXPERIMENTAL
Intervention: SRP+laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 30
Study: 12638337

Group type: EXPERIMENTAL
Intervention: 2D echocardiography (2DE)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Surgical endoventriculoplasty (EVP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 43
Study: 10360804

Group type: EXPERIMENTAL
Intervention: Self-reported symptom survey
Number of subjects: 808

Group type: COMPARATOR
Intervention: Provider-reported symptom assessment
Number of subjects: 808
Study: 7740570

Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 1668907

Group type: EXPERIMENTAL
Intervention: Dilute carbohydrate beverage (C)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Flavored water placebo (P)
Number of subjects: 9
Study: 6812469

Group type: EXPERIMENTAL
Intervention: 2% cromoglycate eye drops
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (cromoglycate and placebo)
Number of subjects: 33
Study: 31896078

Group type: EXPERIMENTAL
Intervention: Physical Activity promotion program
Number of subjects: 122

Group type: COMPARATOR
Intervention: Motor placebo activity (Control)
Number of subjects: 122
Study: 30100379

Group type: EXPERIMENTAL
Intervention: Sorafenib plus topotecan
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo plus topotecan
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 27388862

Group type: EXPERIMENTAL
Intervention: Web-based observational practice (OP) including individual OP and collaborative OP (COP) groups in addition to reading materials (RMs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reading materials (RMs) only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Collaborative OP (COP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Individual OP
Number of subjects: 30
Study: 24894685

Group type: EXPERIMENTAL
Intervention: ACEI
Number of subjects: 1463
Study: 22574612

Group type: EXPERIMENTAL
Intervention: Isoleucine‐Proline‐Proline/Valine‐Proline‐Proline lactotripeptides (LTPs)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 164
Study: 20206670

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (23vPPS) at 12 months
Number of subjects: 552

Group type: COMPARATOR
Intervention: Not receiving 23vPPS at 12 months
Number of subjects: 552
Study: 18981326

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 3790

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3790

Group type: EXPERIMENTAL
Intervention: Chlorthalidone after adjustment for change in serum potassium
Number of subjects: 3790

Group type: EXPERIMENTAL
Intervention: Change in serum potassium
Number of subjects: 3790

Group type: EXPERIMENTAL
Intervention: Chlorthalidone after year 1
Number of subjects: 3790
Study: 16532892

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 29
Study: 12094857

Group type: EXPERIMENTAL
Intervention: Balsalazide (6.75 g daily)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Balsalazide (2.25 g daily)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Mesalamine (2.4 g daily)
Number of subjects: 154
Study: 10379633

Group type: EXPERIMENTAL
Intervention: moexipril 15 mg once daily
Number of subjects: 93

Group type: COMPARATOR
Intervention: nitrendipine 20 mg once daily
Number of subjects: 93
Study: 9289465

Group type: EXPERIMENTAL
Intervention: Phenazone (18 mg/kg body mass) administered orally after surgical ovariectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenazone (18 mg/kg body mass) administered orally before surgical ovariectomy
Number of subjects: 0
Study: 1521399

Group type: EXPERIMENTAL
Intervention: Polymeric probe
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metal probe
Number of subjects: 24
Study: 6499895

Group type: COMPARATOR
Intervention: Clonidine (CLON) 0.2 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moxonidine (MOX) 0.2 mg daily
Number of subjects: 20
Study: 30842109

Group type: EXPERIMENTAL
Intervention: Home-based cardiac exercise rehabilitation with remote electrocardiogram monitoring (REMS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional rehabilitation without monitoring
Number of subjects: 120
Study: 30082268

Group type: EXPERIMENTAL
Intervention: BVS (bioresorbable vascular scaffolds)
Number of subjects: 480

Group type: COMPARATOR
Intervention: CoCr‐EES (cobalt‐chromium everolimus‐eluting stents)
Number of subjects: 480